{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:32:17Z","timestamp":1784118737945,"version":"3.55.0"},"reference-count":57,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda France SAS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Gaucher disease type 1 (GD1) is characterized by hepatosplenomegaly, thrombocytopenia, and disabling bone manifestations requiring regular MRI monitoring. The EIROS study assessed the real-world impact of velaglucerase alfa on GD1 bone disease, using MRI data collected in French clinical practice. Methods: MRIs collected retrospectively from treatment initiation and prospectively during follow-up (12-months) were analyzed centrally by a blinded expert radiologist to evaluate bone infiltration using the Bone Marrow Burden (BMB) score and a qualitative method (stable, improved or worsened for the spine and femur). Abdominal MRIs were also centrally analyzed to assess hepatosplenomegaly. Bone manifestations, hepatosplenomegaly, and hematologic parameters were analyzed from medical records. Results: MRI data were available for 20 patients: 6 treatment-naive patients and 14 patients who switched to velaglucerase alfa from another GD treatment. Interpretable MRIs for BMB scoring were available for seven patients for the spine and one patient for the femur. Qualitative assessments (n = 18) revealed stability in spine and femur infiltration in 100.0% and 84.6% of treatment-switched patients (n = 13), respectively, and improvements in 80.0% and 60.0% of treatment-naive patients (n = 5), respectively; no worsening of bone infiltration was observed. Liver, spleen, and hematologic parameters improved in treatment-naive patients and remained stable in treatment-switched patients. Conclusions: The qualitative real-world data support findings from clinical trials suggesting the long-term effectiveness of velaglucerase alfa on GD1 bone manifestations. When MRI assessment by radiologists with experience of GD is not possible, a simplified qualitative assessment may be sufficient in clinical practice for monitoring bone disease progression and treatment response.<\/jats:p>","DOI":"10.3390\/jcm13102926","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T03:24:48Z","timestamp":1715829888000},"page":"2926","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Monia","family":"Bengherbia","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Referral Center for Lysosomal Diseases, Beaujon Hospital, AP-HP, Universit\u00e9 Paris Cit\u00e9, 92110 Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Biological and Clinical Hematology, Estaing Hospital, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2954-6743","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Hivert","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saint Vincent de Paul Hospital, GHICL, 59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rigaudier","sequence":"additional","affiliation":[{"name":"CEN Biotech, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-8781","authenticated-orcid":false,"given":"Luc","family":"Bracoud","sequence":"additional","affiliation":[{"name":"Clario Inc. (Formerly Bioclinica, Inc.), 69006 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Vaeterlein","sequence":"additional","affiliation":[{"name":"Clario Inc. (Formerly Bioclinica, Inc.), 20355 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Yousfi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Referral Center for Lysosomal Diseases, Beaujon Hospital, AP-HP, Universit\u00e9 Paris Cit\u00e9, 92110 Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maric","sequence":"additional","affiliation":[{"name":"Takeda France SAS, 75116 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Malcles","sequence":"additional","affiliation":[{"name":"Takeda France SAS, 75116 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-741X","authenticated-orcid":false,"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Referral Center for Lysosomal Diseases, Beaujon Hospital, AP-HP, Universit\u00e9 Paris Cit\u00e9, 92110 Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","article-title":"Gaucher disease epidemiology and natural history: A comprehensive review of the literature","volume":"22","author":"Nalysnyk","year":"2017","journal-title":"Hematology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher Disease in Bone: From Pathophysiology to Practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_4","unstructured":"EMA (2022, November 01). European Medicines Agency Summary of Product Characterisics for Imiglucerase. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cerezyme."},{"key":"ref_5","unstructured":"EMA (2022, November 01). European Medicines Agency Summary of Product Characterisics for Velaglucerase Alfa. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vpriv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","article-title":"Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/10600280221108443","article-title":"A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease","volume":"57","author":"Leonart","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcmd.2016.10.007","article-title":"Treatment-naive Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials","volume":"68","author":"Zimran","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: Results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2014.02.006","article-title":"Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up","volume":"53","author":"Elstein","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2011.04.005","article-title":"Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction","volume":"47","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102591","DOI":"10.1016\/j.bcmd.2021.102591","article-title":"Bone marrow burden score is not useful as a follow-up parameter in stable patients with type 1 Gaucher disease after 5 years of treatment","volume":"90","author":"Paskulin","year":"2021","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00330-015-3715-2","article-title":"Bone marrow involvement in Gaucher disease at MRI: What long-term evolution can we expect under enzyme replacement therapy?","volume":"25","author":"Fedida","year":"2015","journal-title":"Eur. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","article-title":"Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1","volume":"17","author":"Dardis","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/jmd2.12342","article-title":"Recommendations on the follow-up of patients with Gaucher disease in Spain: Results from a Delphi survey","volume":"64","author":"Giraldo","year":"2023","journal-title":"JIMD Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","article-title":"Revised recommendations for the management of Gaucher disease in children","volume":"172","author":"Kaplan","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jpeds.2009.07.004","article-title":"Recommendations on diagnosis, treatment, and monitoring for Gaucher disease","volume":"155","author":"Martins","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.15402","article-title":"How we manage Gaucher Disease in the era of choices","volume":"182","author":"Szer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ymgme.2021.12.009","article-title":"Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus","volume":"135","author":"Kishnani","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"ref_26","unstructured":"PNDS (2022, November 01). Protocole National de Diagnostic et de Soins (PNDS): Maladie de Gaucher (2015, Last Reviewed and Updated 2022). Available online: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-05\/pnds_maladie_de_gaucher_cetg_avril_2022.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"The French Gaucher\u2019s disease registry: Clinical characteristics, complications and treatment of 562 patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_28","first-page":"792","article-title":"Report of the Spanish Gaucher\u2019s disease registry: Clinical and genetic characteristics","volume":"85","author":"Giraldo","year":"2000","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.24957","article-title":"Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)","volume":"93","author":"Zimran","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1002\/ajh.24055","article-title":"Understanding the natural history of Gaucher disease","volume":"90","author":"Mistry","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/ajh.24054","article-title":"The history and accomplishments of the ICGG G aucher registry","volume":"90","author":"Weinreb","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ymgmr.2017.10.011","article-title":"Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey","volume":"14","author":"Schwartz","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","article-title":"Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients","volume":"22","author":"Poll","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_34","unstructured":"CETG (2024, March 11). Comit\u00e9 d\u2019Evaluation du Traitement de la maladie de Gaucher [Committee for the Evaluation and Treatment of Gaucher Disease]. Available online: https:\/\/www.cetl.net\/maladies-lysosomales\/cetg-maladie-de-gaucher\/."},{"key":"ref_35","unstructured":"CETG (2023, February 01). Proc\u00e9dure pour la R\u00e9alisation des IRM dans la Maladie de Gaucher. Available online: http:\/\/cetl.net\/maladies-lysosomales\/cetg-maladie-de-gaucher\/documents-d-aide-a-la-prise-en\/documents-d-information-pour-les\/article\/procedure-pour-la-realisaiton-des."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10545-011-9308-6","article-title":"Biomarkers in the diagnosis of lysosomal storage disorders: Proteins, lipids, and inhibodies","volume":"34","author":"Aerts","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_38","unstructured":"(2022, February 01). Gaucher Institute: Diagnosis of Gaucher Disease: Chitotriosidase. Last updated December 2022. Available online: https:\/\/gaucher-institute.com\/differential-diagnosis\/diagnosis-of-gaucher-disease\/chitotriosidase."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher\u2019s disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"Am. J. Roentgenol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10545-018-0195-y","article-title":"Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa","volume":"41","author":"Zimran","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1590\/0100-3984.2014.0068","article-title":"Magnetic resonance imaging and BMB score in the evaluation of bone involvement in Gaucher\u2019s disease patients","volume":"48","author":"Mello","year":"2015","journal-title":"Radiol. Bras."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bcmd.2016.11.004","article-title":"Intraobserver and interobserver variability of the bone marrow burden (BMB) score for the assessment of disease severity in Gaucher disease. Possible impact of reporting experience","volume":"68","author":"Lai","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1055\/s-0035-1553362","article-title":"Evaluation of Bone Marrow Infiltration in Non-Neuropathic Gaucher Disease Patients with Use of Whole-Body MRI--A Retrospective Data Analysis","volume":"187","author":"Laudemann","year":"2015","journal-title":"Rofo"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13244-019-0743-5","article-title":"Imaging of non-neuronopathic Gaucher disease: Recent advances in quantitative imaging and comprehensive assessment of disease involvement","volume":"10","author":"Degnan","year":"2019","journal-title":"Insights Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13023-014-0112-x","article-title":"Modelling Gaucher disease progression: Long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications","volume":"9","author":"Biegstraaten","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/ar3111","article-title":"Bone events and evolution of biologic markers in Gaucher disease before and during treatment","volume":"12","author":"Stirnemann","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.12651","article-title":"Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy","volume":"93","author":"Aerts","year":"2008","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: Effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2010.10.009","article-title":"Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model","volume":"46","author":"Bracoud","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.24040","article-title":"Seven-year safety and efficacy with velaglucerase alfa for treatment-na\u00efve adult patients with type 1 G aucher disease","volume":"90","author":"Zimran","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2010.07.008","article-title":"Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease","volume":"46","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"Hendriks","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2019.236083","article-title":"Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data","volume":"106","author":"Raskovalova","year":"2021","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejrad.2006.11.024","article-title":"S-MRI score: A simple method for assessing bone marrow involvement in Gaucher disease","volume":"62","author":"Roca","year":"2007","journal-title":"Eur. J. Radiol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Revel-Vilk, S., Fuller, M., and Zimran, A. (2020). Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197159"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/10\/2926\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:06Z","timestamp":1760107386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/10\/2926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jcm13102926"],"URL":"https:\/\/doi.org\/10.3390\/jcm13102926","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}